Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 3, 2009, Pages 497-507

  Kim, Won ^a   Yoon, Jung Hwan ^a   Kim, Jung Ryul ^a   Jang, In Jin ^a   Bang, Yung Jue ^a   Kim, Yoon Jun ^a   Lee, Hyo Suk ^a  

^a Seoul National University   (South Korea)

Author keywords

Apoptosis; Hepatocellular carcinoma; Protein kinase C; Statin

Indexed keywords

ENZASTAURIN; MEVINOLIN; PROTEIN KINASE C BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; C3H MOUSE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SIZE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DISEASE PROGRESSION; DRUG SYNERGISM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IN SITU NICK-END LABELING; INDOLES; LIVER NEOPLASMS, EXPERIMENTAL; LOVASTATIN; MALE; MICE; MICE, INBRED C3H; MICROVESSELS; NEOPLASM TRANSPLANTATION; PROTEIN KINASE C;

EID: 67349105662     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0897-1     Document Type: Article

References (50)

1. JM Llovet A Burroughs J Bruix 2003 Hepatocellular carcinoma Lancet 362 1907 1917 (Pubitemid 37518510)
2. HB El-Serag AC Mason 1999 Rising incidence of hepatocellular carcinoma in the United States N Engl J Med 340 745 750 (Pubitemid 29114292)
3. DM Parkin F Bray J Ferlay P Pisani 2001 Estimating the world cancer burden: Globocan 2000 Int J cancer 94 153 156 (Pubitemid 32911406)
4. MF Yuen CC Cheng IJ Lauder SK Lam CG Ooi CL Lai 2000 Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience Hepatology 31 330 335 (Pubitemid 30078596)
5. SJ Myung JH Yoon KM Kim GY Gwak YJ Kim JW Yu JW Chung HS Lee 2006 Diffuse infiltrative hepatocellular carcinomas in a hepatitis B-endemic area: diagnostic and therapeutic impediments Hepatogastroenterology 53 266 270
6. HS Lee KM Kim JH Yoon TR Lee KS Suh KU Lee JW Chung JH Park CY Kim 2002 Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study J Clin Oncol 20 4459 4465 (Pubitemid 35334758)
7. S Louafi V Boige M Ducreux L Bonyhay T Mansourbakht T de Baere A Asnacios L Hannoun T Poynard J Taïeb 2007 Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study Cancer 109 1384 1390 (Pubitemid 46466566)
8. T Matsunaga H Shirasawa T Hishiki H Enomoto K Kouchi Y Ohtsuka J Iwai H Yoshida M Tanabe S Kobayashi T Asano T Etoh Y Nishi N Ohnuma 1998 Expression of MRP and cMOAT in childhood neuroblastomas and malignant liver tumors and its relevance to clinical behavior Jpn J Cancer Res 89 1276 1283 (Pubitemid 29060562)
9. YY Chou AL Cheng HC Hsu 1997 Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: clinical correlation J Gastroenterol Hepatol 12 569 575
10. CL Lai PC Wu GC Chan AS Lok HJ Lin 1988 Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial Cancer 62 479 483 (Pubitemid 18176726)
11. SS Thorgeirsson JW Grisham 2002 Molecular pathogenesis of human hepatocellular carcinoma Nat Genet 31 339 346 (Pubitemid 35154440)
12. P Hentosh SH Yuh CE Elson DM Peffley 2001 Sterol-independent regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in tumor cells Mol Carcinog 32 154 166 (Pubitemid 33055004)
13. WW Wong MM Tan Z Xia J Dimitroulakos MD Minden LZ Penn 2001 Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin Clin Cancer Res 7 2067 2075 (Pubitemid 32994846)
14. T Kubota K Fujisaki Y Itoh T Yano T Sendo R Oishi 2004 Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors Biochem Pharmacol 67 2175 2186 (Pubitemid 38639926)
15. MA Shibata Y Ito J Morimoto Y Otsuki 2004 Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism Carcinogenesis 25 1887 1898 (Pubitemid 39405908)
16. MJ Clemens I Trayner J Menaya 1992 The role of protein kinase C isoenzymes in the regulation of cell proliferation and differentiation J Cell Sci 103 Pt 4 881 887 (Pubitemid 23042231)
17. BA Teicher E Alvarez K Menon MA Esterman E Considine C Shih MM Faul 2002 Antiangiogenic effects of a protein kinase Cbeta-selective small molecule Cancer Chemother Pharmacol 49 69 77
18. S Suzuki H Hayashi K Takagi T Kondo K Takagi J Ueyama S Wakusawa 2006 Protein kinase Cbeta isoform down-regulates the expression of MDR3 P-glycoprotein in human Chang liver cells Biochim Biophys Acta 1760 1552 1557 (Pubitemid 44428026)
19. K Tanaka M Honda T Takabatake 2004 Anti-apoptotic effect of atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardiac myocytes through protein kinase C activation Clin Exp Pharmacol Physiol 31 360 364 (Pubitemid 38803082)
20. PA Welch VP Sinha AL Cleverly C Darstein SD Flanagan LC Musib 2007 Safety, tolerability, QTc evaluation, and pharmacokinetics of single and multiple doses of enzastaurin HCl (LY317615), a protein kinase C-beta inhibitor, in healthy subjects J Clin Pharmacol 47 1138 1151
21. MA Carducci L Musib MS Kies R Pili M Truong JR Brahmer P Cole R Sullivan J Riddle J Schmidt N Enas V Sinha DE Thornton RS Herbst 2006 Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer J Clin Oncol 24 4092 4099 (Pubitemid 46622284)
22. W Feleszko EZ Balkowiec E Sieberth M Marczak A Dabrowska A Giermasz A Czajka M Jakóbisiak 1999 Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis Int J Cancer 81 560 567 (Pubitemid 29203053)
23. H Higuchi SF Bronk Y Takikawa N Werneburg R Takimoto W El-Deiry GJ Gores 2001 The bile acid glycochenodeoxycholate induces trail-receptor 2/DR5 expression and apoptosis J Biol Chem 276 38610 38618
24. H Nakabayashi K Taketa K Miyano T Yamane J Sato 1982 Growth of human hepatoma cells lines with differentiated functions in chemically defined medium Cancer Res 42 3858 3863 (Pubitemid 12054507)
25. YI Yamashita M Shimada H Hasegawa R Minagawa T Rikimaru T Hamatsu S Tanaka K Shirabe JI Miyazaki K Sugimachi 2001 Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model Cancer Res 61 1005 1012 (Pubitemid 32174418)
26. SL Beal 1984 Population pharmacokinetic data and parameter estimation based on their first two statistical moments Drug Metab Rev 15 173 193 (Pubitemid 14123937)
27. WW Wong J Dimitroulakos MD Minden LZ Penn 2002 HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis Leukemia 16 508 519 (Pubitemid 34460459)
28. J Wu WW Wong F Khosravi MD Minden LZ Penn 2004 Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis Cancer Res 64 6461 6468 (Pubitemid 39297901)
29. MD Siperstein VM Fagan 1964 Deletion of the cholesterol-negative feedback system in liver tumors Cancer Res 24 1108 1115
30. Buchwald H (1992) Cholesterol inhibition, cancer, and chemotherapy. Lancet 339:1154-1156
31. P Cafforio F Dammacco A Gernone F Silvestris 2005 Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells Carcinogenesis 26 883 891 (Pubitemid 41214316)
32. G Paragh P Kertai P Kovacs G Paragh Jr P Fulop G Foris 2003 HMG CoA reductase inhibitor fluvastatin arrests the development of implanted hepatocarcinoma in rats Anticancer Res 23 3949 3954 (Pubitemid 37474348)
33. ML Littman T Taguchi EH Mosbach 1966 Effect of cholesterol-free, fat-free diet and hypocholesteremic agents on growth of transplantable animal tumors Cancer Chemother Rep 50 25 45
34. S Kawata E Yamasaki T Nagase Y Inui N Ito Y Matsuda M Inada S Tamura S Noda Y Imai Y Matsuzawa 2001 Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial Br J Cancer 84 886 891 (Pubitemid 32385829)
35. Blais L, Desgagne A, LeLorier J (2000) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 160:2363-2368 (Pubitemid 30799515)
36. MR Graaf AB Beiderbeck AC Egberts DJ Richel HJ Guchelaar 2004 The risk of cancer in users of statins J Clin Oncol 22 2388 2394 (Pubitemid 41115396)
37. R Marais Y Light C Mason H Paterson MF Olson CJ Marshall 1998 Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C Science 280 109 112 (Pubitemid 28169093)
38. C O'Brian VG Vogel SE Singletary NE Ward 1989 Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue Cancer Res 49 3215 3217 (Pubitemid 19162127)
39. E Selzer I Okamoto T Lucas R Kodym H Pehamberger B Jansen 2002 Protein kinase C isoforms in normal and transformed cells of the melanocytic lineage Melanoma Res 12 201 209 (Pubitemid 34666810)
40. TT Wu YH Hsieh CC Wu YS Hsieh CY Huang JY Liu 2007 Overexpression of protein kinase Calpha mRNA in human hepatocellular carcinoma: a potential marker of disease prognosis Clin Chim Acta 382 54 58
41. KA Keyes L Mann M Sherman E Galbreath L Schirtzinger D Ballard YF Chen P Iversen BA Teicher 2004 LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice Cancer Chemother Pharmacol 53 133 140 (Pubitemid 38186992)
42. H Yoshiji S Kuriyama DK Ways J Yoshii Y Miyamoto M Kawata Y Ikenaka H Tsujinoue T Nakatani M Shibuya H Fukui 1999 Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis Cancer Res 59 4413 4418 (Pubitemid 29418762)
43. PG Goekjian MR Jirousek 2001 Protein kinase C inhibitors as novel anticancer drugs Expert Opin Investig Drugs 10 2117 2140 (Pubitemid 34000377)
44. JY Lee YA Hannun LM Obeid 1996 Ceramide inactivates cellular protein kinase Calpha J Biol Chem 271 13169 13174 (Pubitemid 26175896)
45. VL Goss BA Hocevar LJ Thompson CA Stratton DJ Burns AP Fields 1994 Identification of nuclear beta II protein kinase C as a mitotic lamin kinase J Biol Chem 269 19074 19080
46. RX Shi CN Ong HM Shen 2005 Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells Cancer Res 65 7815 7823
47. SC Brady LA Allan PR Clarke 2005 Regulation of caspase-9 through phosphorylation by protein kinase C zeta in response to hyperosmotic stress Mol Cell Biol 25 10543 10555 (Pubitemid 41681975)
48. A Skaletz-Rorowski Y Kureishi I Shiojima K Walsh 2004 The pro- and antiangiogenic effects of statins Semin Vasc Med 4 395 400 (Pubitemid 40577828)
49. Y Kureishi Z Luo I Shiojima A Bialik D Fulton DJ Lefer WC Sessa Walsh 2000 The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals Nat Med 6 1004 1010
50. A Thibault D Samid AC Tompkins WD Figg MR Cooper RJ Hohl J Trepel B Liang N Patronas DJ Venzon E Reed CE Myers 1996 Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer Clin Cancer Res 2 483 491